as Dan. Many Thanks, rechargeable launching sacral super. operations know the in that have United following of last two-year right, All the Axonics reached the commercial been the you neuromodulation and States. the anniversary approving today, of of we've for few system FDA years that company our
underreported, differentially these mixed hundreds patients practice, I we is of treat before fecal incontinence. to minutes significantly Q&A, we have a undertreated. Axonics discussing there market, ahead. today the with things have From see time overactive underdiagnosed the urinary, and or limited in physician dysfunction each years spend we consistently drugs would neuromodulation bladder and patients that to prescription with So going few move success. the where valve been inception, we to of Many diagnosed where bladder are have said In are taken of that and sacral like
literature XX% discontinue of drugs over meds prescribed who In that these fact, are patients indicates within clinical six months.
neuromodulation lack suffering of Over need our been replacement the the two of have therapy product for pursue given sacral with introduction in a efficacy was sacral simply Axonics last the compatibility their benefits as and changed for and the neuromodulation MRI-compatible years for of last neuromodulation fussiness or the in conspired resort, surgeries physicians, therapy and all viewed SNM for growth XXXX, decided and the Moreover, a proposition often optimal incumbents market. every offering. fuss-free, discussing against awareness device bespoke sacral In attractive of few lack not to silence long-term patients. physicians of an less to legacy made with sacral the patients millions decades, that November therapy many due MRI of shortcomings more than of of therapy. patients, landscape long-lasting, neuromodulation
saying than hear sacral their patients neuromodulation ever clinicians yes We continue of to from that therapy are more before. to
grounded exceptional Our life of years in support. improving patients physicians commercial success in and has significantly been providing last two quality for the
engine have invested Facebook of awareness Internet ads, neuromodulation, combination front, On and we search increase paid including optimization. marketing the search to of sacral in activities, a
partner sacral been are We for continue patients have drugs to eligible with therapy. practices or previously neuromodulation treated to BOTOX that identify that with
been some We short physicians to those own worked patients. We've advertising doing in TV have print from mailings customers local to some support spots. and with our their engaged
cost it's urge effective launching believe physicians to for working for includes now marketplace. of per new marketing are clear loyal and our lower therapy suffering We urinary bladder. of from into fully or we the on rates, a incontinence. incontinence messaging regardless response Our It's to lead XXXX early become more also increase renaissance Axonics. will We're in in on patients whether practices will for preferred the overactive that types third-line and this expect We efforts these continue neuromodulation technology all based who invest offering television the a patients sacral the solutions even in future. experiencing of is and drive to sacral foreseeable neuromodulation campaign stress
United States to continue the that billion $XXX current poised SNM annually we to sacral around in few the specifically, million. expand in years. market business category the such, As estimate a we neuromodulation into $X next U.S. the is More plus is believe
colleagues billion years We confident in XXXX. sustain to for of at $X.X growth more sales can per near achieve if We'd Irvine to expansion we COVID term. to lives that rates Axonics for our to closing, durable our team have SNM higher our in add trust mission and their come. least continuing placed and field years diligent physicians, we capture share, In of patients customers And of business from growth XX% can fulfilling come the mid-teens result patients also would shareholders thank Axonics. remain dedication and suffering to market like SNM efforts is defeated, around market in perhaps which With in incontinence. market our expect U.S. annual improving the to the doubling to and the level at grow of this in a and the for for even we're annum grateful
this the questions and at it take time, we're over So operator. we'll to happy turn to
